WANT·WANT

Coty's Q2 earnings decreased, with a net loss reported. Revenue saw a slight increase, but operating income and adjusted EBITDA declined. The company's debt decreased significantly after the Wella sale.

This article discusses GSK's sales increase driven by oncology and HIV drugs. The article highlights a 7% sales rise in 2025. The source is Pharmaceutical Technology.

This article discusses Jim Cramer's assessment of Axon. The summary does not mention WANT.

The article discusses the Net Asset Value (NAV) of a First Trust Global Capital Strength ESG Leaders UCITS ETF. It provides the fund's TIDM, ISIN code, shares in issue, currency, and NAV per share as of February 2, 2026.

Silver47 Exploration Corp. announced a feature article on Kitco discussing silver supply and industrial demand. The article highlights Silver47's position with U.S. assets and a funded drilling strategy. The article is about Silver47, not WANT.

OKYO Pharma announced positive results from a Type C meeting with the FDA regarding its Phase 2b/3 clinical trial for neuropathic corneal pain. The FDA confirmed the study design, sample size, and the use of the Visual Analogue Scale (VAS) for measuring pain reduction. The agency also provided guidance to enhance the study's robustness.